CBB1007 trihydrochloride

Overview

CBB1007 trihydrochloride is a reversible and selective LSD1 inhibitor with an IC 50 of 5.27 µM for human LSD1. CBB1007 trihydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 trihydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 trihydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Histone Demethylase

Product Information

• Catalog No.: HY-15313C
• CAS No.: 2070015-03-9
• Molecular Formula: C27H37Cl3N8O4
• Molecular Weight: 643.99
• Purity: 97.08%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 1.25 mg/mL (1.94 mM); Clear solution
• Availability: In-stock

Source

Original product source